Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

Neutra Corp. (OTCBB: NTRR), a growing provider of all-natural wellness solutions, announced today that it has entered the final stages of negotiations toward a potentially lucrative new partnership in the $1.7 billion U.S. medical marijuana (MMJ) industry.

“We've thoroughly scouted the marketplace for the ideal fit for our company, and all that remains now is to get the contracts signed. If all goes as planned, we anticipate the realization of first revenue within a short period.”

For its first foray into the rapidly expanding health sector, NTRR plans to help market and develop safer, healthier and more advanced cannabinoid delivery systems to patients and care providers who rely on MMJ for the treatment of debilitating illnesses. Topical treatments, oral capsules, throat sprays and other emerging solutions could hold the key to achieving NTRR's aggressive corporate growth goals as more and more patients turn to healthier, more effective alternatives to smoking.

"Both parties extremely excited about this potential partnership," said NTRR CEO Sydney Jim. "We've thoroughly scouted the marketplace for the ideal fit for our company, and all that remains now is to get the contracts signed. If all goes as planned, we anticipate the realization of first revenue within a short period."

For several weeks, NTRR has sought out promising potential partners who are developing breakthrough delivery systems capable of dramatically improving the benefits of prescribed cannabinoids to patients. The effects of throat sprays, oral capsules and topical creams are typically more predictable, more discrete, less invasive and less harmful than smoking cannabis.

"We believe the market potential for this stunning innovation is massive, and growing by the day," Mr. Jim said.

SOURCE Neutra Corp.